J&J suffers setback over heart-stent price cap in U.K.

07/23/2008 | Bloomberg

The British National Institute for Health and Clinical Excellence has denied an appeal from Johnson & Johnson's Cordis unit against a ruling that limits the price of drug-coated stents to no more than $599 above the cost of bare-metal stents. Drug-eluting devices "will continue to be an important treatment option for patients who would be at high risk of requiring further interventions if a bare-metal stent was used instead," NICE CEO Andrew Dillon said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN